Purinergic modulation of cardiovascular function in the rat locus coeruleus.
1 The purpose of the present study was to determine whether purines exerted a physiological role in central cardiovascular modulation at the level of the locus coeruleus (LC). 2 In pentobarbitone-anaesthetised Wistar-Kyoto rats, unilateral microinjection of ATP or alpha,beta-methyleneATP into the LC elicited dose-related decreases in blood pressure and heart rate. Unilateral microinjection of the P2 purinoceptor antagonists suramin and PPADS, caused pressor and tachycardic responses. Administration of the selective P2X(1) receptor antagonist NF-279 had no effect. While both ATP and L-glutamate (L-GLU) resulted in depressor responses after intra-LC microinjection, following intra-LC microinjection of P2 purinoceptor antagonists into the LC, the effects of subsequent administration of either ATP or L-GLU were functionally reversed, such that a pressor response ensued. 3 Microinjection of noradrenaline into the LC caused an increase in blood pressure and heart rate; however, the alpha(2)-adrenoceptor antagonist idazoxan had no cardiovascular effects, but did prevent the pressor response to PPADS or suramin. In addition, coinjection of idazoxan with either suramin or PPADS abolished the ATP and L-GLU mediated pressor responses observed following either suramin or PPADS administration. 4 The present data suggest that firstly, purines are capable of acting within the LC to ultimately modulate the cardiovascular system and secondly, that there is apparently a functional interaction between tonically active purinergic and noradrenergic systems within the LC of the rat.
Yao
Song T
ST
Department of Pharmacology, P.O. Box 13E, Monash University, Victoria 3800, Australia. Song.Yao@bristol.ac.uk
Lawrence
Andrew J
AJ
D000255:Adenosine Triphosphate / Q000494:pharmacology / Q000502:physiology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology*; D008125:Locus Coeruleus / Q000187:drug effects / Q000502:physiology*; D008297:Male; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D011921:Rats, Inbred WKY; D018048:Receptors, Purinergic P2 / Q000502:physiology*
D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D011732:Pyridoxal Phosphate; D000255:Adenosine Triphosphate
J Neurosci. 1981 Aug;1(8):876-86
7346592
Neuroreport. 1994 Aug 15;5(13):1601-4
7819528
Physiol Rev. 1983 Jul;63(3):844-914
6308694
Exp Brain Res. 1984;55(1):145-51
6745345
Am J Physiol. 1984 Oct;247(4 Pt 2):H675-81
6496709
Can J Physiol Pharmacol. 1985 Jun;63(6):599-605
4041999
Brain Res. 1985 Dec 9;358(1-2):77-84
4075133
Neurosci Lett. 1985 Oct 24;61(1-2):25-9
4080257
Science. 1986 Nov 7;234(4777):734-7
3775363
Neurosci Lett. 1986 Nov 21;71(3):299-305
3025783
Hypertension. 1987 Jun;9(6 Pt 2):III110-3
3596777
Brain Res. 1987 Jun 23;414(1):119-32
2887237
Brain Res Bull. 1988 Aug;21(2):191-9
2461245
J Comp Neurol. 1999 Sep 27;412(3):410-28
10441230
J Comp Neurol. 2000 Nov 27;427(4):485-507
11056460
Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):340-50
11111828
Neuroscience. 2001;102(3):593-602
11226696
J Physiol. 2003 Oct 1;552(Pt 1):197-211
12878756
J Pharmacol Sci. 2004 Feb;94(2):153-60
14978353
Br J Pharmacol. 2004 Sep;143(1):119-31
15345659
Kurume Med J. 2004;51(2):109-23
15373228
Brain Res. 1976 Aug 13;112(2):413-9
8191
Brain Res. 1979 Aug 17;172(1):174-8
466462
Brain Res. 1980 Feb 10;183(2):301-11
7353141
Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):26-30
6116197
Science. 1982 Mar 12;215(4538):1394-6
6278591
J Neurosci. 1988 Oct;8(10):3644-57
3193175
Nature. 1989 Aug 24;340(6235):639-42
2570354
J Neurosci. 1991 Mar;11(3):760-9
1672153
Trends Pharmacol Sci. 1991 Sep;12(9):319-24
1658999
Neuroscience. 1992 Jun;48(4):941-52
1630630
Eur J Pharmacol. 1992 Mar 17;213(1):71-7
1499658
Eur J Pharmacol. 1992 Jul 7;217(2-3):217-9
1330591
Brain Res. 1993 Jan 8;600(1):56-62
8093676
J Neurosci. 1993 Mar;13(3):894-9
8441014
Naunyn Schmiedebergs Arch Pharmacol. 1993 Jan;347(1):21-7
8446180
Neurosci Lett. 1993 Apr 16;153(1):1-4
8099722
Br J Pharmacol. 1994 Mar;111(3):913-7
8019769
Neuroscience. 1994 Jul;61(2):199-202
7969901
Br J Pharmacol. 1994 Nov;113(3):815-22
7858872
Brain Res Bull. 1994;35(5-6):513-9
7859109
Br J Pharmacol. 1995 May;115(2):302-6
7670731
Nature. 1995 Oct 5;377(6548):432-5
7566120
Mol Pharmacol. 1995 Oct;48(4):569-73
7476880
J Physiol. 1995 Jul 1;486 ( Pt 1):33-46
7562642
EMBO J. 1996 Jan 2;15(1):55-62
8598206
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3684-8
8622997
J Neurosci. 1996 Apr 15;16(8):2495-507
8786426
Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;352(6):585-96
9053729
J Pharmacol Exp Ther. 1996 Nov;279(2):967-74
8930206
Eur J Pharmacol. 1996 Nov 21;315(3):255-61
8982662
Br J Pharmacol. 1997 Oct;122(3):423-30
9351497
Neuropharmacology. 1997 Sep;36(9):1127-39
9364468
Neuropharmacology. 1997 Sep;36(9):1229-42
9364478
J Neurosci. 1998 Mar 1;18(5):1704-12
9464995
Brain Res. 1998 Jul 20;799(2):278-84
9675311
Pharmacol Rev. 1998 Sep;50(3):413-92
9755289
J Neurosci. 1999 Jan 15;19(2):737-46
9880594
J Comp Neurol. 1999 Apr 28;407(1):11-32
10213185
Neuroscience. 1999;91(2):621-9
10366019
Neurosci Lett. 1994 Jun 20;174(2):188-92
7970176
Naunyn Schmiedebergs Arch Pharmacol. 1982 Oct;321(1):38-43
6292740